Effect of filgotinib on pain in patients with rheumatoid arthritis: results from phase 3 clinical trials

Effect of filgotinib on pain in patients with rheumatoid arthritis: results from phase 3 clinical trials

Bibliographic Details
Main Authors:	Pope, J, Taylor, P, Kavanaugh, A, Nash, P, Bartok, B, Hasegawa, K, Rao, S, Strengholt, S, Westhovens, R
Format:	Conference item
Language:	English
Published:	Journal of Rheumatology 2021

Similar Items

Impact of filgotinib on pain control in the phase 3 FINCH studies
by: Taylor, PC, et al.
Published: (2024)

Impact of filgotinib on pain control in the phase 3 FINCH studies
by: Bruno Fautrel, et al.
Published: (2024-02-01)

Filgotinib for the treatment of rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017)

Concomitant use of statins in filgotinib-treated patients with rheumatoid arthritis
by: Taylor, PC, et al.
Published: (2021)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
by: Mark Genovese, et al.
Published: (2018-03-01)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
by: Bernard Combe, et al.
Published: (2022-10-01)

Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
by: René Westhovens, et al.
Published: (2021-07-01)

Filgotinib, an oral JAK1 selective inhibitor with a rapid onset of action: results from the DARWIN 1 study in methotrexate inadequate response rheumatoid arthritis patients
by: Taylor, P, et al.
Published: (2017)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
by: Alejandro Balsa, et al.
Published: (2023-09-01)

Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid arthritis: results from two randomized, controlled phase 2b trials
by: Tarrant, J, et al.
Published: (2020)

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2024)

Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis
by: Jeffrey R. Curtis, et al.
Published: (2023-12-01)

Patients with high baseline neutrophil-to-lymphocyte ratio exhibit better response to filgotinib as treatment for rheumatoid arthritis
by: Taylor, PC, et al.
Published: (2024)

Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
by: Yoshiya Tanaka, et al.
Published: (2022-11-01)

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study
by: Westhovens, R, et al.
Published: (2016)

Correction: Impact of filgotinib on pain control in the phase 3 FINCH studies
Published: (2024-04-01)

The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile found in the blood of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2018)

Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives
by: Tanaka Y, et al.
Published: (2023-10-01)

Filgotinib, a Janus kinase 1 (JAK1)-selective inhibitor, modulates disease associated cytokines in patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Filgotinib-treated rheumatoid arthritis patients with high baseline neutrophil-to-lymphocyte ratio show better clinical response rates and patient-reported outcomes
by: Taylor, P, et al.
Published: (2021)

Filgotinib modulates inflammation-associated peripheral blood protein biomarkers in adults with active rheumatoid arthritis and prior inadequate response to methotrexate
by: Tanaka, Y, et al.
Published: (2023)

Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-07-01)

Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
by: Yoshiya Tanaka, et al.
Published: (2023-09-01)

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
by: Orbai, A-M, et al.
Published: (2019)

Selective inhibition of Janus kinase 1 (JAK1) by filgotinib modulates the disease-associated whole blood transcriptional profile of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-11-01)

Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid
by: Taylor, P, et al.
Published: (2018)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
by: M. Elaine Husni, et al.
Published: (2022-03-01)

ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice
by: Maurizio Benucci, et al.
Published: (2023-08-01)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
by: Mease, P, et al.
Published: (2018)

Patient perceptions concerning pain management in the treatment of rheumatoid arthritis.
by: Taylor, P, et al.
Published: (2010)

Pain in the joints and beyond; the challenge of rheumatoid arthritis
by: Taylor, P
Published: (2023)

Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
by: Dafna Gladman, et al.
Published: (2023-10-01)

Pain reduction in rheumatoid arthritis patients who use opioids: a post hoc analysis of phase 3 trials of baricitinib
by: Pope, JE, et al.
Published: (2021)

Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-severely Active Rheumatoid Arthritis (FINCH3)
by: Taylor, P, et al.
Published: (2020)

Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
by: Janet E. Pope, et al.
Published: (2022-03-01)

Pain in rheumatoid arthritis - Could JAK inhibition be the answer?
by: Mehta, P, et al.
Published: (2020)

Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
by: Taylor, P, et al.
Published: (2019)

Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate (FINCH1)
by: Taylor, P, et al.
Published: (2020)

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes
by: Taylor, P, et al.
Published: (2022)